Wells Fargo & Company MN raised its stake in shares of STAAR Surgical Company (NASDAQ:STAA) by 30.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,262 shares of the medical instruments supplier’s stock after buying an additional 15,769 shares during the period. Wells Fargo & Company MN owned 0.17% of STAAR Surgical worth $659,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of the stock. Strs Ohio acquired a new stake in STAAR Surgical during the first quarter worth approximately $251,000. Candriam Luxembourg S.C.A. purchased a new stake in shares of STAAR Surgical during the first quarter worth about $441,000. Teachers Advisors LLC boosted its stake in shares of STAAR Surgical by 3.7% in the fourth quarter. Teachers Advisors LLC now owns 71,882 shares of the medical instruments supplier’s stock worth $780,000 after buying an additional 2,549 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of STAAR Surgical by 6.3% in the fourth quarter. State Street Corp now owns 626,735 shares of the medical instruments supplier’s stock worth $6,800,000 after buying an additional 37,175 shares in the last quarter. 75.73% of the stock is owned by institutional investors and hedge funds.

STAAR Surgical Company (NASDAQ:STAA) traded down 1.89% during mid-day trading on Friday, reaching $10.40. The company had a trading volume of 38,747 shares. STAAR Surgical Company has a 1-year low of $6.55 and a 1-year high of $11.50. The firm has a 50-day moving average of $10.27 and a 200 day moving average of $9.89. The company’s market capitalization is $425.69 million.

STAAR Surgical (NASDAQ:STAA) last issued its earnings results on Wednesday, August 2nd. The medical instruments supplier reported ($0.01) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.05) by $0.04. The business had revenue of $21.90 million during the quarter, compared to analyst estimates of $22.15 million. STAAR Surgical had a negative return on equity of 8.74% and a negative net margin of 6.06%. STAAR Surgical’s revenue was up 4.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) EPS. On average, analysts predict that STAAR Surgical Company will post ($0.13) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY NOTICE: This piece was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another site, it was stolen and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/08/04/wells-fargo-company-mn-has-659000-position-in-staar-surgical-company-nasdaqstaa-updated-updated-updated.html.

A number of equities research analysts recently issued reports on STAA shares. Canaccord Genuity boosted their price objective on STAAR Surgical from $9.00 to $11.00 and gave the company a “hold” rating in a research note on Thursday. Zacks Investment Research raised STAAR Surgical from a “sell” rating to a “hold” rating in a report on Wednesday, July 5th.

About STAAR Surgical

STAAR Surgical Company designs, develops, manufactures and sells implantable lenses for the eye and delivery systems used to deliver the lenses into the eye. It operates in the ophthalmic surgical market segment. Its principal products are intraocular lenses used in cataract surgery and implantable collamer lenses used in refractive surgery.

Institutional Ownership by Quarter for STAAR Surgical (NASDAQ:STAA)

Receive News & Stock Ratings for STAAR Surgical Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STAAR Surgical Company and related stocks with our FREE daily email newsletter.